Lactobacillus brevis G-101 strain and use thereof

Abstract

The present invention relates to a novel Lactobacillus brevis G-101 strain capable of decomposing monosodium L-glutamate (MSG), and a functional health food, a pharmaceutical composition, or a food product comprising the same as an active ingredient. More specifically, the strain is effective in reducing in vivo blood MSG levels of animals and attenuating MSG Symptom Complex, and thus can be used in a functional health food, a pharmaceutical composition, or a food product aiming to prevent in vivo absorption of MSG, which is known to be harmful, and improve the MSG Symptom Complex.

Claims

1. A method of treating monosodium glutamate (MSG) symptom complex in a subject in need of such treatment, the method comprising: orally administering an effective amount of live Lactobacillus brevis G-101 of (Accession Number: KCCM11412P) to the subject in need of such treatment.

2. The method of claim 1, wherein the effective amount is 110.sup.10 CFU.

Description

DESCRIPTION OF DRAWINGS

(1) The accompanying drawings illustrate embodiments of the present disclosure and, together with the foregoing disclosure, serve to provide further understanding of the technical features of the present disclosure. However, the present disclosure is not to be construed as being limited to the drawings.

(2) FIG. 1 shows blood MSG concentration over time after administering MSG into the rats administered with the Lactobacillus brevis G-101.

(3) (Con: control group, MSG: group treated with only MSG, G101L: group treated with Lactobacillus brevis 110.sup.9 CFU/rat, G101H: group treated with Lactobacillus brevis 110.sup.10 CFU/rat)

(4) FIG. 2 shows blood MSG Cmax value (left) and AUC value (right) after administering MSG into the rats administered with the Lactobacillus brevis G-101.

(5) (Con: control group, MSG: group treated with only MSG, G101L: group treated with Lactobacillus brevis 110.sup.9 CFU/rat, G101H: group treated with Lactobacillus brevis 110.sup.10 CFU/rat)

(6) FIG. 3a to FIG. 3c show HPLC Chromatogram showing blood MSG concentration over time after administering MSG into the rats administered with the Lactobacillus brevis G-101. FIG. 3a is the result of HPLC Chromatogram subjected to the group treated with only MSG (group not treated with Lactobacillus brevis G-101), FIG. 3b is the result of HPLC Chromatogram subjected to the group treated with Lactobacillus brevis G-101 110.sup.9 CFU/rat, and FIG. 3c is the result of the HPLC Chromatogram subjected to the group treated with Lactobacillus brevis G-101 110.sup.10 CFU/rat.

(7) (Con: control group, MSG: group treated with only MSG, G101 Low: group treated with Lactobacillus brevis 110.sup.9 CFU/rat, G101 High: group treated with Lactobacillus brevis 110.sup.10 CFU/rat, Arrow: MSG)

(8) FIG. 4a and FIG. 4b show HPLC Chromatograms of reaction mixtures incubated with MSG in the presence of Lactobacillus plantarum CLP-0611. FIG. 4a is the result of the HPLC Chromatogram subjected to the group culturing the Lactobacillus plantarum CLP-0611 in MSG-added MRS broth, and FIG. 4b is the result of HPLC Chromatogram subjected to the group in which the Lactobacillus plantarum CLP-0611 cultured in MRS broth was centrifuged to collect only its cell, and the cell was added into MSG-added sterilized purified water and then reacted. (thick arrow: MSG, thin arrow: GABA)

(9) FIG. 5a and FIG. 5b show HPLC Chromatogram of reaction mixtures incubated with MSG in the presence of Lactobacillus brevis G-101. FIG. 5a is the result of the HPLC Chromatogram subjected to the group culturing the Lactobacillus brevis G-101 in MSG-added MRS broth, and FIG. 5b is the result of HPLC Chromatogram subjected to the group in which the Lactobacillus brevis G-101 cultured in MRS broth was centrifuged to collect only its cell, and the cell was added into MSG-added sterilized purified water and then reacted. (thick arrow: MSG, thin arrow: GABA)

(10) FIG. 6a to FIG. 6d show the effect of the Lactobacillus brevis G-101 on inhibition of inflammatory cytokine expression in LPS-stimulated peritoneal macrophages. FIG. 6a shows expression concentration of anti-inflammatory cytokine IL-10, FIG. 6b shows expression concentration of pro-inflammatory cytokine TNF-, FIG. 6c shows expression concentration of IL-, and FIG. 6d shows expression concentration of IL-6. (G3, 110.sup.3 CFU; G4, 110.sup.4 CFU; G5, 110.sup.5 CFU)

(11) FIG. 7 shows effect of the Lactobacillus brevis G-101 on inhibiting of NF-B and AP1 activation in LPS-stimulated peritoneal macrophages. (G3, 110.sup.3 CFU; G4, 110.sup.4 CFU; G5, 110.sup.5 CFU)

(12) FIG. 8 shows inhibition effect of the Lactobacillus brevis G-101 affecting to NF-B, MAPKs and AKT signal pathway in TNBS-induced colitis mice. (G8, 110.sup.8 Lactobacillus brevis G-101; G9, 110.sup.9 Lactobacillus brevis G-101; M10, 10 mg/kg Mesalazine)

(13) FIG. 9 shows inhibition effect of the Lactobacillus brevis G-101 affecting to macrophage polarization marker expression in TNBS-induced colitis mice. (G8, 110.sup.8 Lactobacillus brevis G-101; G9, 110.sup.9 Lactobacillus brevis G-101; M10, 10 mg/kg Mesalazine)

(14) FIGS. 10a-10d show effect of the Lactobacillus brevis G-101 on macroscopic score (FIG. 10a) and colon length (FIG. 10b) of TNBS-induced colitis mice, inhibition effect thereof on myeloperoxidase activity (FIG. 10c) of TNBS-induced colitis mice, and the result of histological exam thereof (FIG. 10d). (G-8 or G101-L, 110.sup.8 Lactobacillus brevis G-101; G-9 or G101-H, 110.sup.9 Lactobacillus brevis G-101; M10, 10 mg/kg Mesalazine)

EMBODIMENTS

(15) Hereinafter, embodiments of the present disclosure will be described in detail with reference to the accompanying drawings. Prior to the description, it should be understood that the terms used in the specification and the appended claims should not be construed as limited to general and dictionary meanings, but interpreted based on the meanings and concepts corresponding to technical aspects of the present disclosure on the basis of the principle that the inventor is allowed to define terms appropriately for the best explanation. Therefore, the description proposed herein is just examples for the purpose of illustrations only, not intended to limit the scope of the disclosure, so it should be understood that other equivalents and modifications could be made thereto without departing from the scope of the disclosure.

EXAMPLES

Example 1. Isolation and Deposit of Lactobacillus Brevis G-101

(16) A strain, which has high activity of decomposing MSG and converting thereof into GABA, was screened from Lactobacillus isolated form kimchi, and the strain showing the highest activity was selected, and then named G-101. As a result of 16S rRNA sequencing, the selected G-101 was confirmed to have homology of 97% or more with Lactobacillus brevis. Thus, it was identified as L. brevis.

Example 2. Effect of Lactobacillus Brevis G-101 on Inhibition of MSG Absorption

(17) (1) Experimental Method

(18) Male SD rats (200-220 g, 8 mice per group) were used as an experimental animal, MSG metabolic activity of intestinal microbiota in the experimental animal was checked before administrating the Lactobacillus brevis G-101. Then, the Lactobacillus brevis G-101 was administered into the experimental animal in an amount of 110.sup.9 CFU/rat and 110.sup.10 CFU/rat. Body weight, MSG concentration, microbial number grown in blood and digestive canal content (stomach, appendix), and harmful microbial enzyme activity in digestive canal were used as measurement index.

(19) {circle around (1)} Analysis of MSG Metabolic Activity of Intestinal Microbiota

(20) In order to check MSG metabolic activity of intestinal microbiota in the experimental animal before administrating the Lactobacillus brevis G-101, intestinal content of the experimental animal administered with MSG was inoculated in MSG-containing MRS broth, cultured for 24 hours, and then MSG metabolic activity was measured by enzymatic analysis.

(21) {circle around (2)} MSG Administration

(22) Lactobacillus was administered into the experimental animal for 3 days, MSG of 40 to 100 mg was orally administered thereinto, and after 15 min, 30 min, 60 min and 12 min, MSG concentration in digestive canal and blood was measured.

(23) {circle around (3)} MSG Analysis

(24) MSG was analyzed by using HPLC (Colum, Waters AccQ-tag column 3.9150 mm; Eluent, acetate-phosphate buffer (AccQ-tag eluent A); Wavelength, Ex: 250 nm, Em 395 nm).

(25) (2) Experimental Result: Effect of Lactobacillus Brevis G-101 on MSG Absorption

(26) As a result of analyzing MSG metabolic activity (specific activity) of the intestinal microbiota in the experimental animal by the enzymatic analysis, the activity was 0.0084 mol/min/mg.

(27) Lactobacillus brevis G-101 (110.sup.9 CFU or 110.sup.10 CFU) was consecutively administered into a mouse for 3 days, and 30 min after the last administration, MSG of 1 g/kg was administered thereinto and then blood MSG was measured.

(28) As a result, as shown in FIGS. 1 to 3, as compared to the group administered with only MSG, it was found that blood MSG concentration was significantly reduced by the administration of the Lactobacillus brevis G-101. Further, after taking MSG, Tmax, time to maximum blood MSG concentration, was not changed as 15 min, but in the case of administering the Lactobacillus brevis G-101 of 110.sup.10 CFU, after taking MSG, in particular, reduction effect of Cmax, maximum blood MSG concentration, and AUC, total amount of MSG absorbed into blood, were excellent (FIG. 2).

Example 3. Effect of Lactobacillus Brevis G-101 on Conversion of MSG into GABA

(29) (1) Experimental Method

(30) As culturing Lactobacillus (Lactobacillus brevis G-101 and Lactobacillus plantarum CLP-0611 strain) together with MSG, conversion rate of MSG into GABA was measured. Two experiments were conducted: a method of inoculating the Lactobacillus (Lactobacillus brevis G-101 and Lactobacillus plantarum CLP-0611 strain) of 1% into MSG-containing MRS broth and then culturing thereof for 24 hours, and a method of inoculating the Lactobacillus (Lactobacillus brevis G-101 and Lactobacillus plantarum CLP-0611 strain) of 1% into MRS broth, culturing thereof for 24 hours, centrifuging thereof to collect cells and then adding the collected cells into MSG-added sterilized purified water to react thereof with the MSG. Whether the MSG was converted into GABA or not was analyzed by HPLC (Colum, Waters AccQ-tag column 3.9150 mm; Eluent, acetate-phosphate buffer (AccQ-tag eluent A); Wavelength, Ex: 250 nm, Em 395 nm).

(31) Further, MSG metabolic activity of the Lactobacillus (Lactobacillus brevis G-101 and Lactobacillus plantarum CLP-0611 strain) was analyzed by enzymatic analysis. Namely, the Lactobacillus (Lactobacillus brevis G-101 and Lactobacillus plantarum CLP-0611 strain) was inoculated into the MSG-containing MRS broth, cultured for 24 hours, and then the conversion rate of MSG was measured by the enzymatic analysis.

(32) (2) Experimental Result: Result of Comparing MSG Decomposing Effect of Lactobacillus Brevis G-101 and Lactobacillus Plantarum CLP-0611

(33) As culturing Lactobacillus brevis G-101 or Lactobacillus plantarum CLP-0611 strain together with MSG for 24 hours, conversion rate of MSG into GABA was measured by HPLC. As a result, as shown in FIG. 4a, FIG. 4b, FIG. 5a, and FIG. 5b, it was found that treatment with Lactobacillus brevis G-101 showed the best conversion rate, and about 2 to 5% of MSG was converted into GABA. In particular, in the case of inoculating the Lactobacillus plantarum CLP-0611 strain of 1% into the MSG-containing MRS broth followed by culturing thereof for 24 hours, the MSG was not converted into GABA. In addition, as a result of analyzing MSG metabolic activity by the enzymatic analysis, specific activity of the G-101 strain cultured in the MRS broth was 0.691 mmol/h/g, and that of the CLP0611 strain was 0.089 mmol/h/g.

Example 4. Effect of Lactobacillus Brevis G-101 on Inflammation Control by Macrophage Polarization

(34) (1) Experimental Method

(35) Male ICR mice (23-25 g, 8 mice per group) were used as an experimental animal, and Lactobacillus brevis G-101 was administered in an amount of 110.sup.9 CFU/rat and 110.sup.10 CFU/rat. Mesalazine was used as a control drug. Body weight, colon length, colonic myeloperoxidase, macroscopic score, colonic IL- TNF-, IL-6, NF-, IKK, p-IKK, iNOS, COX-2 and HE exam were used as measurement index.

(36) {circle around (1)} TNBS-Induced Colitis Animal Model

(37) The experimental animal was lightly anesthetized with ether, and a 1 ml round-tip syringe was inserted into the large intestine in depth of 3.5 to 4 cm through the anus. 100 l of TNBS 2.5 mg/50% ethanol was slowly administered, and then the animal was kept vertically for 30 to 60 sec in order to make the material be spread well in the large intestine. Other experimental procedure was identical with the above colitis model experiment.

(38) {circle around (2)} Myeloperoxidase

(39) 0.5% hexa-decyl-trimethyl-ammonium bromide was added to intestinal mucous membrane tissue, and the tissue was homogenized followed by centrifuging at 8000 rpm for 30 min 1.6 mM tetra-methyl benzidine 100 l, 0.1% H.sub.2O.sub.2 5 l, distilled water 795 l were added to supernatant 100 l, and then enzymatic activity change was measured in time course at 650 nm Enzymatic activity refers to an amount of an enzyme that oxidizes 1 mol/ml of a substrate at 37 C. and is expressed as Unit/mg protein. Amount of protein was measured according to Bradford method.

(40) {circle around (3)} Western Blot Analysis

(41) Protein was obtained from intestinal mucous membrane by using lysis buffer. Loading buffer was added to the protein 50 g followed by heating at 98 C. for protein denaturation. And, the protein was loaded on 10% SDS electrophoresis gel, and then transferred to a PVDF membrane at 30 V for 2 hours. It was blocked with 5% skim milk for about 2 hours, and then a primary antibody was bound thereto. It was washed with PBST, and then a secondary antibody was bound thereto. It was soaked in ECL solution to attach a fluorescent material, and then exposed to light and developed on a film.

(42) (2) Experimental Result

(43) {circle around (1)} Effect of Lactobacillus Brevis G-101 on Anti-Inflammatory Cytokine Production in Macrophage

(44) In order to search Lactobacillus having anti-inflammatory effect from fermented food, Lactobacillus, which increases anti-inflammatory cytokine IL-10 production in LPS-induced peritoneal macrophage, was searched. As a result, the Lactobacillus brevis G-101 showed the strongest IL-10 production increasing effect, and when treated with the Lactobacillus brevis G-101 110.sup.5 CFU/ml, the production was recovered to 90% or more of normal cells. The Lactobacillus brevis G-101 inhibited inflammatory cytokines, TNF-, IL- and IL-6, in the LPS-stimulated peritoneal macrophage in a concentration-dependent manner (FIG. 6a to FIG. 6d). Further, the Lactobacillus brevis G-101 inhibited activation of inflammatory cytokine transcription factors, NF- and AP1 (FIG. 7).

(45) {circle around (2)} Evaluation of Influence of Lactobacillus Brevis G-101 on Inflammatory Reaction Pathway

(46) In order to confirm the anti-inflammatory effect of the Lactobacillus brevis G-101, inflammation signal pathways of NF-B, MAPKs and AKT were measured. When treated with TNBS on a normal animal, it was observed that both of NF- and MAPKs were activated, but activation was significantly inhibited in the group administered with the Lactobacillus brevis G-101. Further, the Lactobacillus brevis G-101 also inhibited IRAK1 phosphorylation reaction of the above inflammatory pathway. From this result, it was estimated that the Lactobacillus brevis G-101 regulates the upper pathway of the inflammatory reaction pathway (FIG. 8).

(47) {circle around (3)} Effect of Lactobacillus Brevis G-101 on Macrophage Polarization Control

(48) In the TNBS-induced colitis model animal, effect of controlling inflammatory cytokine expression and macrophage polarization was measured. Due to the TNBS treatment, inflammatory reaction-related M1 macrophage markers, ARGII, TNF- and IL-1 were significantly increased, but those were inhibited by administration of the Lactobacillus brevis G-101. Further, M2 macrophage markers, ARG I, CD206 and IL-10 were inhibited by the TNBS, but those were increased by administration of the Lactobacillus brevis G-101 (FIG. 9).

(49) {circle around (4)} Anti-Colitis Effect of Lactobacillus Brevis G-101

(50) Anti-colitis effect of the Lactobacillus brevis G-101 was measured in the TNBS-induced colitis model animal. When treated with the TNBS on a normal animal with the TNBS, colitis index, macroscopic score, was increased (FIG. 10a), myeloperoxidase activity was increased (FIG. 10b), colon length was shortened (FIG. 10c), and tissue was changed (FIG. 10d). However, as a result of oral administration of the Lactobacillus brevis G-101, it could be observed that the colitis index was significantly inhibited.

Example 5. MSG Symptom Complex Attenuation Effect of Lactobacillus Brevis G-101

(51) (1) Experimental Method

(52) 30 people experienced MSG Symptom Complex symptoms were selected, took the Lactobacillus brevis G-101 followed by eating MSG-added rice with Black Soybean Sauce, and then degree of MSG Symptom Complex symptoms was examined for about 12 days.

(53) {circle around (1)} Selection and Presentation of Sample

(54) Both of a test group and a placebo food group were provided with a preparation in the form of 300 mg/capsule, and instructed to take 1 capsule/day. The test group took a capsule, which was manufactured to contain 10 billion of Lactobacillus brevis G-101 per capsule (300 mg) by mixing Lactobacillus brevis G-101 freeze-dried powder and maltodextrin, and the placebo food group took a capsule filled with 300 mg of maltodextrin per capsule.

(55) For inducing MSG Symptom Complex, rice with black soybean sauce, in which the sauce contained 6 g of MSG in one portion, was prepared, and then provided to inspectors. The rice with black soybean sauce (one portion) was made of rice (180 g) and black soybean sauce (pork 40 g, Mirim Ts, onion 40 g, zucchini 40 g, carrot 30 g, cabbage 50 g, black soybean paste 1 Ts, cooking oil Ts, seasoning (MSG, A company) 6 g, starch-water 2 Ts).

(56) {circle around (2)} Inspector

(57) As an inspector, a panel was constituted with 30 selected people experienced MSG Symptom Complex symptoms, and any beverage or food other than water was not provided to the inspectors from 1 hour before evaluation.

(58) {circle around (3)} Evaluation Content and Procedure

(59) The inspectors were educated about characteristics of MSG Symptom Complex, divided into groups A and B, provided with G101 preparation or placebo food, and took thereof for 5 days. They were allowed to take the rice with black soybean sauce through total 2 visits. In order to ensure fairness for tasting, both preparations were provided as 300 mg/capsule not to let them know whether they took the G101 preparation or the placebo food, double blind placebo controlled study was conducted, and then the second test was conducted after the first test was completed.

(60) In the first test (duration: 5 days), from Day 1 of research participation, the inspectors took the G101 preparation or the placebo food every day about at 10 a.m., and they visited at Day 5, took the rice with black soybean sauce about at noon, and then allowed to self-record about degree of MSG Symptom Complex symptoms (5 score scale: 1=No Symptom, 5=Strong Symptom), kinds and expression time of MSG Symptom Complex symptoms, and time spent on disappearance of the symptoms on questionnaire items.

(61) Next week, the second test (Duration: 5 days) was identically conducted except for exchanging the G101 preparation or the placebo food between the groups A and B.

(62) Namely, the first experiment and the second experiment were conducted as listed in the following Table.

(63) TABLE-US-00001 TABLE 1 Whether Lactobacillus Panel preparation was provided or not Collection Group Mon Tue Wed Thu Fri First Group A Test Group B X X X X X Take rice with black soybean sauce at noon Second Group A X X X X X Test Group B Take rice with black soybean sauce at noon

(64) {circle around (4)} Statistical Treatment

(65) Data was statistically treated using SAS Program 9.3. Significance of the data expressed as frequency and percentage was verified using .sup.2, and as the result of examining MSG Symptom Complex after eating the MSG-added rice with black soybean sauce by scoring the symptoms, preference was expressed as meanstandard deviation, difference between intake or non-intake of the Lactobacillus was verified using T-test.

(66) (2) Experimental Result

(67) {circle around (1)} MSG Symptom Complex Symptoms after Eating Rice with Black Soybean Sauce

(68) 30 people experienced MSG Symptom Complex symptoms were selected out of people in their 20s to constitute a panel. The panel took the Lactobacillus preparation and the placebo preparation at the identical time in the morning for 5 days and the MSG-added rice with black soybean sauce, and then degree of MSG Symptom Complex symptoms was examined. As a result, as shown in Table 2, significance was shown depending on intake or non-intake of the Lactobacillus (p=0.0031).

(69) In the G101 intake group, slight subjective symptoms of MSG Symptom Complex was 33.3%, which was higher than 20% in the G101 non-intake group, and also in the G101 intake group, moderate subjective symptoms of MSG Symptom Complex was 46.7%, which was higher than 16.7% in the G101 non-intake group. However, in the G101 non-intake group, slightly strong subjective symptoms of MSG Symptom Complex was 43.3%, which was higher than 20.0% in the G101 intake group, and in the G101 non-intake group, strong subjective symptoms of MSG Symptom Complex was 20%, but it was 0% in the G101 intake group.

(70) Through this result, in both of the G101 intake group and the non-intake group, the subjective symptoms of MSG Symptom Complex after eating the MSG-added rice with black soybean sauce was shown, but it was found that the intake of the G101 can effectively inhibit the subjective symptoms of MSG Symptom Complex.

(71) TABLE-US-00002 TABLE 2 Lactobacillus Brevis G101 Symptom Intake group Non-intake group (Intensity) N (%) N (%) None 0(0.0) 0(0.0) .sup.2 = 13.8421 Slight 10(33.3) 6(20.0) df = 4 Moderate 14(46.7) 5(16.7) p = 0.0031 Slightly Strong 6(20.0) 13(43.3) Strong 0(0.0) 6(20.0) Total 30(100.0) 30(100.0)

(72) Further, after eating the MSG-added rice with black soybean sauce, the symptoms of MSG Symptom Complex was scored (1=No Symptom, 5=Strong Symptom). As a result, as shown in Table 3, the subjective symptoms of MSG Symptom Complex in the G101 intake group (2.87) was significantly lower than that in the G101 non-intake group (3.63) (p=0.0016).

(73) TABLE-US-00003 TABLE 3 Lactobacillus Brevis G101 Intake group Non-intake group T-value Male (N = 10) + 2.87 0.73 3.63 1.03 3.32 Female (N = 20) (p = 0.0016) Total (N = 30)

(74) The result of selecting all subjective symptoms of MSG Symptom Complex after eating the MSG-added rice with black soybean sauce was thirstiness (81.7%), drowsiness (66.7%), weakness (26.7%), tightness (11.7%), headache (10.0%), nausea (10.0%), dizziness (8.3%), indigestion (1.7%), palpitation (1.7%) and flushing (1.7%) in order, and there was no difference on the subjective symptoms according to whether the G101 was taken or not.

(75) TABLE-US-00004 TABLE 4 Lactobacillus Brevis G101 Non-intake Symptom Intake group group Total Thirstiness 26(86.7) 23(76.7) 49(81.7) .sup.2 = 3.5043(p = 0.3169) Weakness 6(20.0) 10(33.3) 16(26.7) .sup.2 = 1.3636(p = 0.2429) Palpitation 0(0.0) 1(3.3) 1(1.7) .sup.2 = 1.0169(p = 0.3132) Tightness 2(6.7) 5(16.7) 7(11.7) .sup.2 = 1.4555(p = 0.2276) Flushing 0(0.0) 1(3.3) 1(1.7) .sup.2 = 1.0169(p = 0.3132) Dizziness 1(3.3) 4(13.3) 5(8.3) .sup.2 = 1.9636(p = 0.1611) Headache 3(10.0) 3(10.0) 6(10.0) .sup.2 = 0.0000(p = 1.0000) Nausea 2(6.7) 4(13.4) 6(10.0) .sup.2 = 0.7407(p = 0.3894) Drowsiness 21(70.0) 19(63.3) 40(66.7) .sup.2 = 0.3000(p = 0.5839) Indigestion 0(0.0) 1(3.3) 1(1.7) .sup.2 = 1.0169(p = 0.3132) Total 30(100) 30(100) 60(100)

(76) {circle around (2)} MSG Symptom Complex Symptom Expression Time after Eating Rice with Black Soybean Sauce

(77) How long it will take to make the subjective symptoms of MSG Symptom Complex disappear was examined, and the result was shown in Table 5. As can be seen in Table 5, 96% or more of the subjective symptoms of MSG Symptom Complex disappeared within less than 4 hours in the G101 intake group, but 23.4% of the subjective symptoms of MSG Symptom Complex disappeared within less than 4 to 6 hours in the G101 non-intake group. Namely, in the G101 intake group, 69.9% of the MSG Symptom Complex symptoms disappeared within less than 3 hours, but only 39.0% of the MSG Symptom Complex symptoms disappeared in the G101 non-intake group within the same time period.

(78) TABLE-US-00005 TABLE 5 Lactobacillus Brevis G101 Intake group Non-intake group Time N (%) N (%) <1hr 4(13.3) 2(6.7) .sup.2 = 11.1404 1 hr time < 2 hr 10(33.3) 5(16.5) df = 6 2 hr time < 3 hr 7(23.3) 5(16.7) p = 0.0841 3 hr time < 4 hr 8(26.7) 11(36.7) 4 hr time < 5 hr 0(0.0) 6(20.0) 5 hr time < 6 hr 0(0.0) 1(3.4) 6 hr 1(3.4) 0(0.0) Total 30(100.0) 30(100.0)

INDUSTRIAL APPLICABILITY

(79) The Lactobacillus brevis G-101 according to the present invention showing anti-inflammatory activity is effective to improve, prevent, and treat inflammatory diseases, has excellent MSG decomposing ability, and in particular, exerts superior effect on inhibition of in vivo MSG absorption of an animal based on probiotic activity, which can maintain strain activity in a digestive canal, and excellent effect on attenuation of MSG Symptom Complex. Thus, it is expected to have various types of industrial applicabilities, for example, it can be used as a functional health food, a pharmaceutical composition, or a food product.

(80) [Recognition of the Deposit of MicroorganismsAccession Number: KCCM11412P/Deposit Date: Apr. 30, 2013]

(81) The present disclosure has been described in detail. However, it should be understood that the detailed description and specific examples, while indicating embodiments of the disclosure, are given by way of illustration only, since various changes and modifications within the scope of the disclosure will become apparent to those skilled in the art from this detailed description.